Sanofi Genzyme

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, rare blood disorders, multiple sclerosis, oncology and immunology. Its approach is shaped by a long history of developing highly specialized treatments and by close relationships with physician and patient communities. The unit carries forward the Genzyme name, which is recognized for pioneering treatments for rare genetic disorders and for contributions to medical science and biomanufacturing.

Genzyme was founded in Boston in 1981 and grew rapidly into one of the world’s leading biotechnology companies. It became part of Sanofi in 2011 and, while continuing to focus on rare diseases, established itself as a leader in multiple sclerosis. In 2016 its focus expanded to include Sanofi’s oncology and immunology programs, and in 2018 the acquisitions of Bioverativ and Ablynx added rare blood disorders, bringing deep expertise in hematology.

What to Know

• Parent company Sanofi is headquartered in Paris.
• Sanofi’s wider portfolio also covers vaccines and general medicine, including work on RSV.
• Sanofi Genzyme is listed by the Kendall Square Association in Cambridge.